AstraZeneca to present data at ESC Congress 2019 that potentially redefines the treatment of heart failure

AstraZeneca will present results from the Farxiga (dapagliflozin) Phase III DAPA-HF trial at the ESC Congress in Paris, making Farxiga the first medicine in its class to move into a new disease area by demonstrating efficacy and safety data for the treatment of patients with heart failure.

The results of the DAPA-HF trial in patients with and without type-2 diabetes (T2D), on top of standard of care, is among 28 abstracts that will be presented by AstraZeneca at the congress that takes place from 31 August to 4 September 2019.

Three late-breaking abstracts will be presented on Sunday 1 September, including results from the Brilinta Phase III THEMIS trial and THEMIS-PCI, a sub-analysis of patients with T2D and coronary artery disease (CAD) who had undergone percutaneous coronary intervention. Additionally, new insights from DECLARE-TIMI 58 examine the potential of Farxiga to reduce the rate of adverse CV events in patients with T2D, both with and without kidney disease.

Joris Silon, Senior Vice President, Cardiovascular, Renal and Metabolism, BioPharmaceuticals said: "The presentation of our Phase III trials at the ESC Congress clearly demonstrates AstraZeneca's commitment to advance treatments where there is a need to improve patient outcomes in cardiovascular disease. With the Farxiga DAPA-HF trial, we explored the potential benefits of this medicine, an SGLT2 inhibitor, for the treatment of patients with heart failure, with and without type-2 diabetes. With Brilinta, the THEMIS trial demonstrated the potential of this medicine in patients with coronary artery disease and diabetes who are at high-risk of having a cardiovascular event." 

Key AstraZeneca abstracts at the ESC Congress 2019 include:

Lead Abstract title Presentation details
author
Brilinta  
Jones, WS Effect of Poster Presentation: #P935. Saturday 31 August,
Hypertension and 11:00-16:00, Posters - Poster Area
Systolic Blood
Pressure on
Cardiovascular
and Limb
Outcomes in
Patients with
Symptomatic
Peripheral
Artery Disease:
the EUCLID
Trial.
Russo, J Predictors of Moderated Poster Presentation: #1932. Sunday 1
DAPT Use in September, 12:40-13:30, Moderated ePoster 2 -
Patients Beyond Poster Area
One-Year Post
-Myocardial
Infarction:
Insights from
the TIGRIS
Observational
Study.
Hasvold, Cardiovascular Poster Presentation: #2207. Sunday 1 September,
P Outcome in 14:30-14:38, Agora 2 - Poster Area
THEMIS-like Type
-2 Diabetes
Patients in
Sweden: A
Nationwide
Observational
Study.
Bhatt, D THEMIS - Main Late-Breaking Science: #2097. Sunday 1 September,
Results of the 14:30-14:43, Paris - Main Auditorium Session
Effect of
Ticagrelor on
Health Outcomes
in Diabetes
Mellitus
Patients
Intervention
Study.
Steg, G THEMIS-PCI: Late-Breaking Science: #2098. Sunday 1 September,
Ticagrelor in 14:43-14:48, Paris - Main Auditorium
Patients with
Diabetes and
Stable Coronary
Artery Disease
with a History
of Prior
Percutaneous
Coronary
Intervention.
Nicolau, Baseline Poster Presentation: #P5471. Tuesday 3 September,
JC Characteristics, 8:30-12:30, Posters - Poster Area
Healthcare
Resource Use and
Clinical
Outcomes of
Stable Post
-Myocardial
Infarction
Patients with
Diabetes:
Insights from
the Global
Prospective
TIGRIS Study.
Danchin, Diabetes and Late-Breaking Science: #5904. Tuesday 3
N Heart Failure September, 14:48-15:06, Budapest - Village 5
after Acute
Myocardial
Infarction. The
FAST-MI
Programme.
Farxiga  
Zelniker, Effect of Oral Presentation: #192. Saturday 31 August,
T Dapagliflozin on 11:18-11:36, Reykjavik - Village 2
Cardiovascular
Outcomes in
Patients with
Type-2 Diabetes
According to
Baseline Renal
Function and
Albuminuria
Status: Insights
from DECLARE
-TIMI 58.
Berg, D Heart Failure Oral Presentation: #410. Saturday 31 August,
Risk 14:37-14:55, Reykjavik - Village 2
Stratification
and Efficacy of
Dapagliflozin in
Patients with
Type-2 Diabetes
Mellitus.
McMurray, DAPA-HF - The Late-Breaking Science. Sunday 01 September, 15:38
J Dapagliflozin - 15:51, Paris - Main Auditorium
and Prevention
of Adverse
-outcomes in
Heart Failure
Trial.

For a complete list of AstraZeneca data presentations at ESC Congress 2019, please access the ESC Congress website here (http://spo.escardio.org/default.aspx?eevtid=1423&showResults=False).

About DAPA-HF

DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) is the first heart failure trial with an SGLT2 inhibitor and morbidity and mortality outcomes investigating the treatment of heart failure on top of standard of care, in a representative patient population (NYHA II to IV) with and without type-2 diabetes. DAPA-HF is an international, multi-centre, parallel group, randomised, double-blind trial in patients with heart failure and reduced ejection fraction (LVEF ≤ 40%), with and without type-2 diabetes, designed to evaluate the effect of Farxiga 10mg, compared with placebo, given once daily in addition to standard of care. The primary composite outcome was time to a worsening heart failure event (hospitalisation or equivalent event; i.e. an urgent heart failure visit), or cardiovascular death.

About THEMIS

THEMIS (Effect of Ticagrelor on Health Outcomes in DiabEtes Mellitus Patients Intervention Study) is an AstraZeneca-sponsored, multi-national, randomised, double-blinded trial in patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior myocardial infarction or stroke. THEMIS was designed to test the hypothesis that Brilinta plus aspirin would reduce major adverse cardiovascular events (MACE), a composite of CV death, myocardial infarction or stroke, compared to aspirin alone. CAD was defined as a history of percutaneous coronary intervention (PCI), bypass surgery or at least a 50% narrowing of a coronary artery. More than 19,000 patients were randomised across 42 countries in Europe, Asia, Africa, North and South America.

About AstraZeneca in CVRM

Cardiovascular, Renal & Metabolism (CVRM) together forms one of AstraZeneca's three therapy areas and is a key growth driver for the Company. By following the science to understand more clearly the underlying links between the heart, kidneys and pancreas, AstraZeneca is investing in a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. The Company's ambition is to modify or halt the natural course of CVRM diseases and potentially regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and cardiovascular health for millions of patients worldwide.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com (http://www.astrazeneca.com/) and follow us on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).

Media Relations    
Gonzalo Viña   +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Sweden +46 8 552 53 106
Malmberg
Hägerstrand
Michele Meixell US +1 302 885 2677
     
Investor    
Relations
Thomas Kudsk   +44 203 749 5712
Larsen
Henry Wheeler Oncology +44 203 749 5797
Christer BioPharmaceuticals (CV, metabolism) +44 203 749 5711
Gruvris
Nick Stone BioPharmaceuticals (respiratory, renal) +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Corporate access, retail investors +44 203 749 5824
Kretzmann
US toll-free   +1 866 381 72 77